NTLA

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a genome editing company founded in 2014 and headquartered in Cambridge, Massachusetts. The company went public in May 2016 and focuses on developing revolutionary therapeutic treatments using CRISPR/Cas9 gene editing technology. Intellia has positioned itself as a leader in the emerging field of precision gene editing, developing both in vivo treatments that work directly inside patients' bodies and ex vivo therapies that modify cells outside the body before reintroduction. The company has advanced multiple programs into late-stage clinical trials and is preparing for its first potential commercial launches in the mid-2020s.